lumos
pharma
participate
november
investor
conferences
austin
texas
globe
newswire
lumos
pharma
nasdaq
lumo
biopharmaceutical
company
focused
therapeutics
rare
diseases
announced
company
present
host
meetings
following
virtual
investor
conferences
held
november
stifel
healthcare
conference
november
lumos
pharma
management
participate
fireside
chat
monday
november
et
host
virtual
meetings
throughout
day
jefferies
london
healthcare
conference
november
lumos
pharma
management
participate
fireside
chat
tuesday
november
et
host
virtual
meetings
throughout
day
please
contact
stifel
jefferies
sales
representatives
participate
investor
conferences
schedule
virtual
meeting
lumos
pharma
management
team
live
webcasts
presentation
available
company
website
investors
media
section
events
archived
edition
presentation
available
company
website
later
day
day
lumos
pharma
presents
lumos
pharma
lumos
pharma
biopharmaceutical
company
focused
development
commercialization
therapeutics
rare
diseases
lumos
pharma
founded
led
management
team
longstanding
experience
rare
disease
drug
development
received
early
funding
leading
healthcare
investors
including
deerfield
management
fund
managed
blackstone
life
sciences
roche
venture
fund
new
enterprise
associates
nea
sant√©
ventures
ucb
lumos
pharma
lead
therapeutic
candidate
oral
growth
hormone
stimulating
small
molecule
treatment
pediatric
growth
hormone
deficiency
pghd
approved
fda
would
provide
orally
administered
alternative
daily
injections
current
pghd
patients
endure
many
years
treatment
received
orphan
drug
designation
us
eu
information
please
visit
investor
media
contact
lisa
miller
lumos
pharma
investor
relations
ir
source
lumos
pharma
inc
